Alnylam Pharmaceuticals (ALNY) to Post Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $1.63 per share and revenue of $1.3180 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. On average, analysts expect Alnylam Pharmaceuticals to post $7 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ:ALNY opened at $266.99 on Thursday. The firm has a market capitalization of $35.65 billion, a PE ratio of 72.95 and a beta of 0.27. The business has a 50 day simple moving average of $293.02 and a two-hundred day simple moving average of $317.88. Alnylam Pharmaceuticals has a 1 year low of $264.21 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Bank of America cut their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Friday, July 10th. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. decreased their target price on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating for the company in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $452.13.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALNY. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $27,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $29,000. Golden State Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $39,000. Finally, Colonial Trust Co SC grew its position in shares of Alnylam Pharmaceuticals by 160.5% during the 4th quarter. Colonial Trust Co SC now owns 99 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.